Atamparib - Ribon Therapeutics
Alternative Names: ONO-7119; RBN-2397Latest Information Update: 28 Jan 2025
At a glance
- Originator Ribon Therapeutics
- Developer Ono Pharmaceutical; Ribon Therapeutics
- Class Amines; Antineoplastics; Ethers; Fluorinated hydrocarbons; Ketones; Piperazines; Pyridazines; Pyrimidines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 7 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Squamous cell cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in Japan (PO)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, In adults) in Spain (PO)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, In adults) in USA (PO)